Total Payments
$5,982
2024 Payments
$1,001
Companies
14
Transactions
67
Medicare Patients
7,941
Medicare Billing
$1.8M
Payment Breakdown by Category
Consulting$2,878 (48.1%)
Food & Beverage$2,285 (38.2%)
Travel$796.78 (13.3%)
Education$22.68 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,878 | 2 | 48.1% |
| Food and Beverage | $2,285 | 62 | 38.2% |
| Travel and Lodging | $796.78 | 1 | 13.3% |
| Education | $22.68 | 2 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $4,430 | 14 | $0 (2024) |
| Astellas Pharma US Inc | $657.78 | 34 | $0 (2024) |
| Kite Pharma, Inc. | $330.43 | 7 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $135.01 | 1 | $0 (2024) |
| Novo Nordisk Inc | $125.00 | 1 | $0 (2024) |
| Legend Biotech USA Inc. | $96.92 | 1 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $75.13 | 2 | $0 (2023) |
| Current Health Inc. | $30.81 | 1 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.60 | 1 | $0 (2024) |
| Daiichi Sankyo Inc. | $17.38 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,001 | 19 | Kite Pharma, Inc. ($313.22) |
| 2023 | $1,392 | 20 | Janssen Scientific Affairs, LLC ($1,000) |
| 2022 | $301.97 | 4 | Janssen Scientific Affairs, LLC ($301.97) |
| 2021 | $90.67 | 5 | Astellas Pharma US Inc ($78.75) |
| 2020 | $70.71 | 4 | Astellas Pharma US Inc ($70.71) |
| 2019 | $3,110 | 14 | Janssen Scientific Affairs, LLC ($2,998) |
| 2017 | $15.80 | 1 | Astellas Pharma US Inc ($15.80) |
All Payment Transactions
67 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2024 | Janssen Scientific Affairs, LLC | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $53.98 | General |
| Category: Oncology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $135.01 | General |
| Category: Hematology | ||||||
| 12/04/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: CELLT | ||||||
| 11/22/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $4.16 | General |
| Category: CELLT | ||||||
| 11/13/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $96.92 | General |
| 11/12/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $142.52 | General |
| Category: CELLT | ||||||
| 09/24/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $30.99 | General |
| Category: Infectious Diseases | ||||||
| 09/16/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: CELLT | ||||||
| 09/09/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $29.15 | General |
| Category: Infectious Diseases | ||||||
| 08/20/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: Infectious Diseases | ||||||
| 08/20/2024 | Astellas Pharma US Inc | Xospata (Drug) | Education | In-kind items and services | $10.76 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $121.35 | General |
| Category: CELLT | ||||||
| 07/11/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Obesity | ||||||
| 06/20/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: CELLT | ||||||
| 06/11/2024 | Janssen Scientific Affairs, LLC | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $75.89 | General |
| Category: Oncology | ||||||
| 05/06/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $27.45 | General |
| Category: Infectious Diseases | ||||||
| 02/26/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $28.95 | General |
| Category: Infectious Diseases | ||||||
| 02/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $29.60 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $29.76 | General |
| Category: Oncology | ||||||
| 12/11/2023 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Infectious Diseases | ||||||
| 11/29/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $29.66 | General |
| Category: Oncology | ||||||
| 10/17/2023 | Current Health Inc. | — | Food and Beverage | Cash or cash equivalent | $30.81 | General |
| 09/11/2023 | Janssen Scientific Affairs, LLC | DARZALEX (Drug) | Food and Beverage | In-kind items and services | $59.00 | General |
| Category: Oncology | ||||||
| 08/23/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 44 | 2,151 | 10,238 | $1.3M | $294,187 |
| 2022 | 41 | 1,929 | 29,607 | $2.3M | $411,639 |
| 2021 | 41 | 1,836 | 33,369 | $1.6M | $344,445 |
| 2020 | 45 | 2,025 | 61,622 | $3.1M | $746,073 |
Total Patients
7,941
Total Services
134,836
Medicare Billing
$1.8M
Procedure Codes
173
All Medicare Procedures & Services
173 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 180 | 2,017 | $498,199 | $124,605 | 25.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 141 | 540 | $198,720 | $51,612 | 26.0% |
| 90670 | Pneumococcal vaccine, 13-valent | Office | 2023 | 22 | 39 | $22,230 | $9,860 | 44.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 41 | 93 | $65,751 | $9,746 | 14.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 154 | 892 | $57,088 | $9,232 | 16.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 11 | 53 | $49,979 | $8,855 | 17.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 63 | 83 | $39,010 | $7,898 | 20.2% |
| 83735 | Magnesium level | Office | 2023 | 154 | 890 | $25,810 | $5,847 | 22.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 66 | 85 | $21,165 | $5,344 | 25.2% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 154 | 884 | $27,404 | $5,233 | 19.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 130 | 566 | $20,376 | $4,307 | 21.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 12 | 63 | $13,293 | $3,673 | 27.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 117 | 415 | $8,300 | $3,486 | 42.0% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 24 | 99 | $14,157 | $3,468 | 24.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 37 | 61 | $19,093 | $3,128 | 16.4% |
| 90746 | Hepatitis b vaccine, adult dosage (3 dose schedule) | Office | 2023 | 22 | 39 | $6,406 | $2,690 | 42.0% |
| 84100 | Phosphate level | Office | 2023 | 113 | 578 | $13,872 | $2,688 | 19.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 31 | 38 | $9,500 | $2,506 | 26.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $10,170 | $2,369 | 23.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 39 | 102 | $16,014 | $2,361 | 14.7% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 14 | 16 | $8,368 | $2,245 | 26.8% |
| 38241 | Transplantation of patient-derived stem cells | Facility | 2023 | 15 | 15 | $35,010 | $2,092 | 6.0% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 90 | 330 | $11,220 | $2,092 | 18.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 28 | 53 | $7,155 | $2,062 | 28.8% |
| 80197 | Tacrolimus level | Office | 2023 | 22 | 145 | $14,645 | $1,952 | 13.3% |
About John Mathews
John Mathews is a Medical Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2010. The National Provider Identifier (NPI) number assigned to this provider is 1568776391.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, John Mathews has received a total of $5,982 in payments from pharmaceutical and medical device companies, with $1,001 received in 2024. These payments were reported across 67 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($2,878).
As a Medicare-enrolled provider, Mathews has provided services to 7,941 Medicare beneficiaries, totaling 134,836 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 173 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Internal Medicine
- Location Dallas, TX
- Active Since 08/04/2010
- Last Updated 09/22/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1568776391
Products in Payments
- DARZALEX (Biological) $2,982
- Yescarta (Drug) $313.22
- Cresemba (Drug) $273.81
- DARZALEX (Drug) $273.02
- IMBRUVICA (Drug) $240.72
- XOSPATA (Drug) $183.32
- REBLOZYL (Biological) $135.01
- CARVYKTI (Drug) $129.87
- Wegovy (Drug) $125.00
- Xospata (Drug) $121.90
- AMBISOME (Drug) $78.75
- MOZOBIL (Drug) $40.92
- REZUROCK (Drug) $34.21
- LIVTENCITY (Drug) $29.60
- Vanflyta (Drug) $17.38
- Epkinly (Drug) $14.88
- MONJUVI (Drug) $14.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Dallas
Dr. Moshe Levy, Md, MD
Medical Oncology — Payments: $5.0M
Medical Oncology $5.0M
Dr. Eric Nadler, Md, MD
Medical Oncology — Payments: $1.8M
Medical Oncology $1.8M
Dr. Joyce O'shaughnessy, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Thomas Hutson, Do,Pharmd, DO,PHARMD
Medical Oncology — Payments: $1.3M
Medical Oncology $1.3M
Dr. Tian Zhang, M.d, M.D
Medical Oncology — Payments: $395,066
Medical Oncology $395,066
Dr. Ashwani Agarwal, M.d, M.D
Medical Oncology — Payments: $304,262
Medical Oncology $304,262